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Available online 2 May 2019Background: Acetylcysteine (NAC) is effective at preventing liver injury after paracetamol overdose. The Scottish
and Newcastle Anti-emetic Pre-treatment for Paracetamol Poisoning (SNAP) Study demonstrated that a 12 h
NAC regimen was associated with fewer adverse drug reactions compared with the standard 21 h regimen.
Here, we describe the clinical effectiveness of the SNAP NAC regimen.
Methods: The SNAP regimen, consisting of intravenous NAC 100 mg/kg over 2 h then 200 mg/kg over 10 h, was
introduced to treat all paracetamol overdose patients at the Royal Infirmary of Edinburgh, the Royal Victoria In-
firmary, Newcastle and St Thomas' Hospital, London. Patient data were prospectively and systematically col-
lected before and after the change in treatment (total patients N = 3340, 21 h N = 1488, SNAP N = 1852).
Health record linkage was used to determine patient outcome after hospital discharge.
Findings: There was no difference in liver injury or liver synthetic dysfunction between regimens. Hepatotoxicity
(peak ALT N 1000 U/L) occurred in 64 (4.3%) and 67 (3.6%) patients, respectively, in the 21 h and SNAP groups
(absolute difference−0.7%, 95% CI−2.1 to 0.6). Multivariable logistic regression did not identify treatment reg-
imen as an outcome-associated factor. No patients were readmitted to hospital with, or died from, liver failure
within 30 days of discharge. Anti-histamine treatment (for NAC anaphylactoid drug reactions) was prescribed
for 163 (11.0%) patients with the 21 h regimen and 37 (2.0%) patients with the SNAP regimen (absolute differ-
ence 9.0% (95% CI 7.3 to 10.7)).
Interpretation: In clinical use the SNAP regimenhas similar efficacy as standard therapy for preventing liver injury
and produces fewer adverse reactions.nd Newc
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Paracetamol (acetaminophen) overdose is one of the most common
reasons for emergency hospital attendance and the leading cause of
acute liver failure in theWestern world [1]. Annually in the UK, paraceta-
mol overdose results in approximately 100,000 Emergency Department
presentations and 50,000 acute hospital admissions [2], and is the direct
cause of death in around 150 people [3]. Deaths or episodes of acute
liver failure in patients who start treatment within 8 hours (h) of a single
acute overdose are extremely rare because of the ease of availability of a
highly effective antidote, acetylcysteine (NAC). This antidote replenishes
cellular glutathione, which protects hepatocytes against injury from the
toxic paracetamol metabolite N acetyl p benzoquinone imine (NAPQI)-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in Context
Evidence Before This Study
Paracetamol overdose is a common reason for emergency ad-
mission to hospital and the commonest cause of acute liver failure
in Europe and North America.
Acetylcysteine (NAC) is effective at preventing liver injury, but
the optimal regimen has not been defined.
We have previously demonstrated that a shorter 12 h NAC
regimen (the ‘SNAP’ regimen) produces fewer adverse reactions.
Added Value of This Study
In this study we demonstrate that the SNAP regimen has com-
parable effectiveness to the standard 21 h NAC regimen at
preventing liver injury in 3340 patients treated at 3 UK hospitals.
Implications of All the Available Evidence
This study provides an evidence base for clinical practice to
change to using the SNAP regimen as standard care for treatment
of paracetamol overdose. This is because this treatment regimen
improves treatment safety for this patient group, reduces the
need for treatment interruptions and potentially shortens the
length of treatment without compromising the effectiveness of
NAC at preventing liver injury.
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poisoning have been implemented in the UK. These guidelines recom-
mend treating all patients with a paracetamol concentration above a sin-
gle treatment line on the paracetamol nomogram (the 100 mg/L at 4 h
after overdose treatment line — ‘100-line’) and treating all patients with
a staggered overdose or uncertain time of ingestion [5].
NAC has been administered intravenously using the same 21 h regi-
men since the 1970s with few dose-finding studies being performed in
this area. This regimen consists of three sequential, weight-related,
doses of NAC given intravenously in 5% dextrose: 150mg/kg bodyweight
over 15 min (extended in the UK to 1 h in 2012), followed by 50 mg/kg
over 4 h and 100 mg/kg over 16 h. This NAC regimen is associated with
a high incidence of adverse drug reactions (ADRs), in particular anaphy-
lactoid reactions [6]. These are unpleasant for patients, result in tempo-
rary cessation of therapy, require anti-histamine treatment, extend the
duration of treatment and hospitalisation, and sometimes cause doctors
towithholdNAC. In addition to ADRs, other problems are thatmedication
errors occur because theNAC regimen is complex [7] and treatment leads
to significant hospital bed occupancy because the regimen is time con-
suming (around 47,000 bed days per year in England) [2].
To address these issues with the 21 h NAC regimen different treat-
ment regimens have been introduced into clinical practice. These in-
clude simplified 1 or 2 ‘bag’ regimens [8,9] or stopping NAC before the
endof the 21 h regimen in very low risk patients [10]. To date, these reg-
imens have not been assessed with robust studies to determine efficacy
and safety, We used pharmacokinetic modelling to design a 12 h NAC
regimen (known as the Scottish and Newcastle Anti-emetic Pre-
treatment for Paracetamol Poisoning Study regimen or “SNAP regi-
men”) which delivers the same dose of NAC as the 21 h regimen
(300 mg/kg) but does not result in the high early blood NAC concentra-
tions associated with anaphylactoid reactions and other ADRs [11]. A
randomised clinical trial that compared the SNAP NAC regimen to the
standard 21 h NAC regimen reported a substantial reduction in ADRs
with the new regimen [6].Due to the reduction in ADRs, simplicity and apparently equivalent
effectiveness, clinical units have started to use the SNAP regimen. On
28th September 2015 it was adopted into clinical practice for all pa-
tients requiring NAC treatment for paracetamol overdose at the Royal
Infirmary of Edinburgh (RIE), UK. Clinical outcome was recorded in
the long-running prospective audit of paracetamol poisoning within
the RIE from before and after the change. On 1st June 2016 and 1st Oc-
tober 2016, the SNAP regimenwas introduced into routine clinical prac-
tice for all patients at St Thomas' Hospital (STH), London and the Royal
Victoria Infirmary (RVI), Newcastle, respectively. Here we compare the
effectiveness of the SNAP regimen with that of the 21 h regimen in an
observational study involving 3340 unselected patients with paraceta-
mol poisoning.2. Methods
2.1. Edinburgh Patient Data
Patient data were collected as part of a long-running, prospective,
audit of consecutive patients admitted with paracetamol overdose to
RIE. This hospital provides the only Emergency Department for the
City of Edinburgh, UK. The change to using the SNAP regimenwas a clin-
ical decision approved by the local NHS governance process. The NHS
Caldicott Guardian approved collection of data using the Toxicology
Unit's paracetamol care pathway data collection form. Prospective
data collection, using a proforma, encompassed two years before and
after the introduction of the SNAP regimen (4 years total).
We included all consecutive patients admitted to RIE with paraceta-
mol overdose that required NAC according to current UK management
guidelines. The UK criteria for starting treatment with NAC are de-
scribed in detail on the UK poisons management database TOXBASE
(www.toxbase.org). In brief, patients taking a single acute overdose
(all tablets ingested within 1 h) were treated if their timed blood para-
cetamol concentrationwas above the 100-line. The decision to treat pa-
tients taking a staggered overdose (deliberate overdose overmore than
1 h) was based on the Medicines and Healthcare Products Regulatory
Agency's (MHRA) guidance published in 2012, which stated that all pa-
tients should receive NAC [5]. There were no changes to the guidelines
during the 4-year period of this study. The pattern of overdose referred
to as therapeutic excess is defined as an accidental overdose with the
tablets taken for therapeutic indications.
From 28 September 2013 to 27 September 2015 patients received
intravenous NAC using the 21 h NAC regimen: 150 mg/kg body weight
over 1 h, followed by 50 mg/kg over 4 h and 100 mg/kg over 16 h
(300 mg/kg total). One hour before the end of treatment blood was
drawn for measurement of liver function tests, creatinine and interna-
tional normalised ratio (INR) to determine whether treatment could
be safely stopped after 21 h of NAC using the criteria outlined below.
From 28 September 2015 to 27 September 2017 patients were
treated with the SNAP regimen: 100 mg/kg over 2 h then 200 mg/kg
over 10 h (300mg/kg total). Two hours before the end of this 12 h treat-
ment regimen blood was drawn and NAC treatment was stopped after
12 h if the following criteria were satisfied: INR 1.3 or less; and alanine
transaminase activity (ALT) b100 U/L and not more than doubled from
admission; and paracetamol concentration b20 mg/L. If these criteria
were not reached then NAC was continued at 200 mg/kg over a further
10 h. Irrespective of whether NAC was continued or discontinued, the
local protocol was for patients to have further blood sampling 20 h
after starting NAC to determine the need for extended treatment (at
the equivalent time to the 21 h regimen). For the 21 h and SNAP regi-
mens the same UK national criteria for stopping NAC treatment after
21 h were used: INR 1.3 or less and ALT b 100 U/L and ALT not more
than doubled from admission. Blood results were collected from
TrakCare software application (InterSystems Corporation, Cambridge,
Massachusetts), an electronic patient record system used by the Acute
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2.2. London and Newcastle Patient Data
Data were collected during previous audits of use of the conven-
tional 21 h NAC regimen following implementation in September
2012. The SNAP regimenwas introduced on 1st June 2016 and 1st Octo-
ber 2016 at STH and RVI, respectively, after approval by the local NHS
clinical governance process. Data were collected with local approval
from the Caldicott Guardian. All paracetamol overdose patients requir-
ing NAC were identified for treatment using the same national criteria
as RIE. The 21 h regimen was delivered as per RIE. For SNAP treatment,
the same patient care pathway was used at STH and RVI; and the same
12 h SNAP regimen was used at all 3 sites. At the end of the 12 h SNAP
regimen blood samples were taken for liver function, creatinine, INR
and paracetamol concentration; if these blood tests were less than
24 h after the last dose of paracetamol, the blood tests were repeated
at 24 h. NAC was continued if the following criteria were met on either
of these blood tests: ALTmore than 2×upper limit of normal or doubled
from admission, or INR more than 1.3, or paracetamol concentration
more than 10 mg/L. Blood results were collected from the STH and RVI
local electronic patient record systems.
2.3. Identification of Anaphylactoid Reactions and Liver Toxicity
In all 3 centres anti-histamine prescribing was used to estimate the
rate of anaphylactoid reactions with both the 21 h and SNAP regimens.
The diagnosis of paracetamol-induced liver injury was made from ALT
and INR measurement. The peak value from each hospital admission
was used for analysis.
2.4. Scottish Data Linkage
Hospital admission and mortality data were obtained from the na-
tional hospitalisation register (Scottish Morbidity Record, SMR01) and
the National Records of Scotland death registrations, respectively. The
SMR01 is a population-based register of hospital admission episodes oc-
curring in Scotland, and holds information on patient conditions leading
to admission. Ethical approval to use fully anonymised collated datawas
provided by National Services Scotland Information Governance. Index
cases admitted to RIE were identified where the ICD-10 diagnosis
code T39.1 (Poisoning by, adverse effect of and underdosing of 4-
Aminophenol derivatives) was present as either the primary diagnosis
or was present in any diagnostic position. The time windows for analy-
sis were 28th September 2012 to 27th September 2015 (21 h NAC reg-
imen) and 28th September 2015 to 27th September 2017 (SNAP
regimen). The following outcomes were measured and expressed as
rate per 1000 admissions: incidence of hospital readmission within
7 days and 30 days of the index case (due to liver failure (see below
for definition), paracetamol overdose (T39.1), all other causes), death
within 7 days and within 30 days of index case (liver failure, all other
causes) and transfer to the Scottish Liver Transplant Unit (7 days and
30 days of index case). Liver failure was defined by ICD-10 codes K72
hepatic failure NEC, K711 Toxic liver failure with hepatic necrosis (in-
cludes hepatic failure (acute) (chronic) due to drugs). The Scottish
Liver Transplant Unit is the only transplant unit covering the Scottish
population.
2.5. Statistical Analysis
Liver injury was quantified by multiple cut-off values for ALT and
INR. Hepatotoxicity was defined as a peak ALT N 1000 U/L and this def-
inition was used as the outcome for subsequent statistical analysis. Due
to slight differences in the delivery of the SNAP regimen across centres
we have considered the data from RVI and STH together and they arepresented both separately and combined with data from RIE. The data
are presented as the number of cases expressed as a percentage of the
relevant total. For liver injury the denominator used was the respective
number of patients starting NAC treatment (unless otherwise stated).
Proportionswere compared across treatment groups by themethod de-
scribed by Newcombe (1998 — method 10) [12]. Differences are pre-
sented as the absolute percentage change and 95% confidence
intervals. Positive absolute changes indicate a higher proportion in the
SNAP regimen group than in the 21 h NAC regimen treated group. For
data from Scottish data linkage the numbers are represented as rate
per 1000 admissions.
We used R, version 3.4.4, for multivariable logistic regression analy-
ses to assess the strength of association between a combination of pa-
tient variables and both hepatotoxicity (ALT N 1000 U/L) and hepatic
synthetic dysfunction (INR N 2). The following variables were included
in this analysis: patient age, gender, weight, paracetamol dose ingested,
dose ingestion per kg bodyweight, presentationALT beforeNAC started,
presentation paracetamol concentration, presentation INR, presentation
serum creatinine concentration, position on paracetamol treatment no-
mogram (single acute overdose only), time from overdose to starting
NAC (single acute overdose only), treatment centre and treatment pro-
tocol (21 h or SNAP). Position on the nomogram was derived from the
paracetamol concentration and time from overdose to blood sampling
using nomograms based on the standard Rumack-Matthew and Pres-
cott nomograms [13,14]: ND (paracetamol not detected), b100,
100–149, 150–199, 200–299 and N300 mg/L. All continuous variables
were scaled and mean centred to aid meaningful interpretation of the
intercept. Due to the predictive interest of the study, patients with the
following data were excluded: missing value for presentation ALT (85
patients), missing value for presentation INR (417 patients), presenta-
tion ALT N 1000 U/L (40 patients) and/or presentation INR N 2 (39 pa-
tients). The dataset was split into acute single overdose with complete
data (1549 patients) and staggered overdose and therapeutic excess
with complete data (1001 patients). Separate models were derived for
these two sub-datasets. Singular variables that were significant (p b
0.05) in univariable logistic regression were entered into stepwise se-
lection processes to obtain a final multivariable model.
Based on clinical expertise, it was hypothesised that the SNAP proto-
col could have a differing effect in those presenting later at hospital
(more than 8 h) after an acute single overdose compared to those pre-
senting before. To test this hypothesis, an interaction term of the binary
indicator of time from overdose to starting NAC being greater than 8 h
and the treatment protocol was fitted with the factors in the final
model.
2.6. Role of Funding Source
The Association of Physicians UK Young Investigator Award was
used to fundhealth record data linkage. This funder had no involvement
in data analysis or paper writing.
3. Results
3.1. Edinburgh Data
In the two-year period preceding the change of regimen there were
1350 patients admitted to RIEwith a diagnosis of paracetamol overdose.
Of these, 1075 (79.6%) were treated with the conventional intravenous
21 h NAC regimen. After clinical adoption of the SNAP regimen 1272 pa-
tients were admitted and 1137 (89.4%) were treated. There were no de-
mographic differences between the patient populations, although there
were proportionally more patients starting NAC 8–24 h after a single
acute overdose in the pre-change cohort and proportionally more stag-
gered overdoses in the SNAP cohort (Table 1). The patient flow before
and after regimen change is presented in Supplementary Fig. 1.
Follow-on blood results at 20 h after starting NAC were available in
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for 20 h blood results not being available are described in Supplemen-
tary Table 1). The 10 h blood results for patients without follow-on
20 h results demonstrated the following values: median (IQR): paracet-
amol concentration 5 mg/L (b5–7); ALT 17 U/L (12–27); INR 1.2
(1.1–1.2). Of these there were 29 patients with an ALT activity greater
than the local upper limit of normal (50 U/L) at 10 h (median 82 U/L
(65–131, maximum 961)). In 23 of the 29 patients their ALT activity
had fallen fromadmission to 10h (meandecrease 25U/L). The overdose
types of these SNAP treated patients — who had 10 h bloods without
20 h bloods — were 79% single acute ingestions who presented within
8 h of overdose, 9% acute presenting greater than 8 h and 12% staggered
overdose. All acute ingestions were below the 200 line on the nomo-
gram, 69% were below the 150 line.
In the 2-year period using the conventional 21 h NAC regimen 127
(11.8%) of the treated RIE patients had an anaphylactoid reaction as es-
timated by prescription of an anti-histamine drug. By contrast, in the 2-
year period using the SNAP regimen 18 (1.6%) of the treated patients re-
ceived anti-histamine treatment. This represents an absolute risk reduc-
tion (ARR) of 10.2% (95% CI 8.2 to 12.4; number needed to treat to
prevent one anti-histamine prescription 10). Within the time windows
included in this study, 37 patientswere treatedwithNAC at RIE both be-
fore and after the regimen change, representing 198 admission episodes
of which 81 episodes were treated with the 21 h NAC regimen and 117
with the SNAP regimen. In these repeat-presenting patients, anaphylac-
toid reactions occurred 5 times with the 21 h regimen (6.2% of total ep-
isodes) and once with the SNAP regimen (0.9%) (ARR: 5.3% (95% CI 0.1
to 12.8)).
Table 2 presents the comparison of the effectiveness of the two reg-
imens with regard to preventing liver injury as quantified by the peak
hospital stay ALT activities and INR values. These data are presented as
a proportion of those patients commencing NAC treatment. Hepatotox-
icity (peakALTN 1000U/L) occurred in 47patients (4.4%)with 21hNAC
and 44 patients (3.9%) with SNAP (absolute difference−0.5%, 95% CI
−2.2 to 1.2). When hepatotoxicity is represented as a proportion of
those patients who had blood sampling at 20 h after starting NAC the
absolute difference between regimens was 0.6% (95% CI −1.4 to 2.6.
21 h regimen 47/1009, SNAP 44/843).
3.2. London and Newcastle Data
At RVI and STH413 patientswere treatedwith the 21 hNAC regimen
and 715 patients were treated with the SNAP regimen. The demo-
graphics of these patients are presented in Table 1. Anti-histamine treat-
ment was prescribed for 36 (8.7%) patients treated with the 21 h
regimen and 19 (2.7%) patients treated with the SNAP regimen (ARRable 1
atient demographics. Patients are grouped by hospital and NAC treatment regimen. RIE = Royal Infirmary of Edinburgh. RVI = Royal Victoria Infirmary, Newcastle. STH = St Thomas'
ospital London. 21 h regimen is the conventional NAC treatment, 12 h regimen is the SNAP regimen. Data are presented asmedian and IQR or numbers and percentage. P values for com-
arison between the RIE treatment regimenswere obtainedbyMann–WhitneyU test or test of proportions. ALT is the serumalaninine transaminase activity. ULN=upper limit of normal.
RIE
21 h regimen
N = 1075
RIE
12 h regimen
N = 1137
RIE
21 h v 12 h
P value
STH & RVI
21 h regimen
N = 413
STH & RVI
12 h regimen
N = 715
STH & RVI
21 h v 12 h
P value
Demographics
Age (years) (IQR) 32 (21–44) 33 (22–45) 0.06 30 (22–45) 32 (23–48) 0.2
Female (number, (%)) 755 (70) 806 (71) 0.6 237 (57) 425 (59) 0.5
Dose ingested:
Single overdose (median mg/kg (IQR)) 212 (148–294) 217 (151–314) 0.3 250 (175–370) 229 (159–333) 1.0
Repeated overdose (median mg/kg (IQR)) 145 (109–222) 151 (113–213) 0.8 180 (117–308) 170 (119–263) 0.3
Time to starting NAC after overdose:
b8 h (number, (%)) 530 (49) 520 (46) 0.2 131 (32) 230 (32) 1.0
8–24 h (number, (%)) 160 (15) 126 (11) 0.005 95 (23) 124 (17) 0.01
N24 h (number, (%)) 36 (3) 28 (2) 0.1 12 (3) 17 (2) 0.3
Staggered overdose (number, (%)) 177 (16) 292 (26) b0.0001 89 (22) 154 (22) 1.0
Therapeutic excess (number, (%)) 164 (15) 164 (14) 0.8 62 (15) 157 (3) b0.0001
ALT N ULN at presentation (number, (%)) 162 (15) 190 (17) 0.2 64 (15) 91 (13) 0.3
Received activated charcoal (number, (%)) 3 (0.3) 9 (0.8) 0.1 6 (1.5) 23 (3.2) 0.076-
.-
1-
%
(-
9-
5-
%
CI
3-
.3
to
9-
.-
3-
)).
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pWith the21h and SNAP regimens, hepatotoxicity (peakALT N 1000U/L)
occurred in 17 (4.1%) and 23 (3.1%) patients, respectively (absolute dif-
ference−0.9%, 95% CI−3.5 to 1.3) (Table 2).
3.3. Combined Data
When all patients were included (21 h N = 1488, SNAP N = 1852)
anti-histamine treatment was prescribed for 163 (11.0%) patients with
the 21 h regimen and 37 (2.0%) patients with the SNAP regimen (ARR
9% (95% CI 7.3 to 10.7)). Fig. 1 presents the absolute differences in the
percentage of patients developing liver injury. Hepatotoxicity occurred
in 64 (4.3%) and 67 (3.6%) patients in the 21 h and SNAP treatment
groups, respectively (absolute difference −0.7%, 95% CI−2.1 to 0.6)
(Table 2).
Multivariable logistic regression analysis was performed to explore
the relationship between treatment regimen and known factors associ-
ated with liver injury (Supplementary Table 2). Five factors were signif-
icant (p = 0.05 or less) predictors of a peak ALT N 1000 U/L as the
outcome in acute single overdose patients: The magnitude of these ef-
fects were ordered as “ND” nomogram (β= −6.9, reduction in out-
come probability) (p = 0.0012), INR (β = 0.99, increase) (p = 3.7
× 10−13), paracetamol concentration (β = 0.73, increase) (p = 2.8
× 10−7), ALT (β= 0.64, increase) (p = 8.4 × 10−9) and the time from
overdose to starting NAC treatment (β = 0.42, increase) (p = 4
× 10−4). The beta-coefficients represent the increase in the value of
the outcome variable for each one standard deviation increase in the
covariate's value. With ALT N 1000 U/L as the outcome in staggered
and therapeutic excess patients, there were 3 statistically significant
factors at presentation. The magnitude of these effects was ordered as
INR (β= 0.77, increase) (p = 2 × 10−5), paracetamol concentration
(β= 0.66, increase) (p = 0.0019) and ALT (β= 0.49, increase) (p =
2.8 × 10−4).
With INR N 2 as the outcome in acute single overdose patients, there
were 3 statistically significant factors at presentation: INR (β= 1.1, in-
crease) (p = 6.9 × 10−13), paracetamol concentration (β= 0.91, in-
crease) (p = 9.2 × 10−9) and ALT (β = 0.33, increase) (p = 9.6
× 10−5). In staggered and therapeutic excess patients, the same 3 fac-
tors were statistically significant: INR (β = 0.93, increase) (p = 3.5
× 10−7), paracetamol concentration (β = 0.72, increase) (p = 8.4
× 10−4) and ALT (β= 0.25, increase) (p = 0.032).
The treatment regimenusedwas not a significant factor in any of the
4 models, with the lowest p-value (p = 0.07) being observed in covar-
iate testing with the ALT N 1000 U/L outcome in staggered patients
(SNAP protocol reducing the frequency of the outcome). Further p-
values (0.30, 0.43 and 0.26) for the ALT N 1000U/L outcome in acute sin-
gle overdose, INR N 2 outcome in acute single overdose and INR N 2
Table 2
Frequency of liver injury after paracetamol overdose. Patients are grouped by hospital and NAC treatment regimen. RIE = Royal Infirmary of Edinburgh. RVI = Royal Victoria Infirmary
Newcastle. STH= St Thomas' Hospital London. 21 h regimen is the conventional NAC treatment, 12 h regimen is the SNAP regimen. Data from the 2 regimens are compared by presenting
the absolute difference in percentage of patients with the defined degree of liver injury and 95% confidence intervals of that difference. All patients are included from the 3 hospital sites
RIE
21 h regimen
RIE
12 h regimen
RIE
Absolute % difference
(95% CI)
STH & RVI
21 h regimen
STH & RVI
12 h regimen
STH & RVI
Absolute % difference
(95% CI)
21 h v 12 h overall
absolute % difference
(95% CI)
Number of patients starting NAC 1075 1137 – 413 715 – –
Extended treatment beyond 21 h (N, (%)) 113 (11) 131 (12) 1.0 (−1.6 to 3.6) 47 (11) 40 (6) −5.8 (−9.5 to 2.5) −1.5 (−3.6 to 0.5)
Peak ALT N 100 U/L (N, (%)) 131 (12) 141 (12) 0.2 (−2.5 to 3.0) 48 (12) 77 (11) −0.9 (−4.8 to 2.8) −0.3 (−2.5 to 1.9)
Peak ALT N 150 U/L (N, (%)) 108 (10) 109 (10) 0.5 (−3.0 to 2.0) 18 (4) 56 (8) 3.5 (0.5 to 6.2) 0.4 (−1.5 to 2.3)
Peak ALT N 1000 U/L (N, (%)) 47 (4) 44 (4) −0.5 (−2.2 to 1.2) 17 (4) 23 (3) −0.9 (−3.5 to 1.3) −0.7 (−2.1 to 0.6)
Peak INR N 2 (N, (%)) 35 (3) 37 (3) 0 (−1.5 to 1.5) 10 (2) 23 (3) 0.8 (−1.4 to 2.7) 0.2 (−1.0 to 1.4)
Peak INR N 3 (N, (%)) 16 (2) 17 (2) 0 (−1.1 to 1.1) 3 (1) 9 (1) 0.5 (−1.0 to 1.7) 0.1 (−0.7 to 0.9)
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15J.M. Pettie et al. / EClinicalMedicine 11 (2019) 11–17outcome in staggered and therapeutic excess patients suggests no sig-
nificant difference in endpoints in SNAP protocol patients compared to
the standard 21 h antidote regimen patients.
3.4. Pattern of Overdose
Patients taking staggered overdoses and those who start treatment
with NAC later than 8 h after a single overdose are at greater risk of
liver injury. Therefore, we analysed the combined dataset by overdose
type (Fig. 2). With regard to the endpoint of ALT N 1000 U/L there was
an effect that favoured the 21 h regimen in the 8–24 group (absolute
difference 3.7% (0.5 to 7.2)) and an effect that favoured SNAP in the
staggered group (absolute difference−2.9% (−6.0 to−0.6)) (Supple-
mentary Table 3). Taking into account the optimal multivariable model
for baseline variables (described above) in the late presenting patients
resulted in a non-significant p-value of 0.06 for ALT N 1000 U/L. As al-
ready described, in themultivariable model derived for staggered over-
doses, treatment regimen is not a significant factor when baseline
variables are accounted for (p = 0.07). There was no effect of regimen
on reaching the endpoint INR N 2 in any sub-group (Supplementary
Table 3). Patients taking larger paracetamol overdoses are at higher
risk of liver injury [15,16]. Therefore, we analysed the combined dataset. 1. The difference in the frequency of liver injury between the 21 h NAC regimen and
e SNAP regimen. A range of cut-off values for serum ALT activity and INR are
esented. Extended treatment refers to having NAC treatment continued after the
imen finishes. Data are presented as the absolute differences (%) with the error bars
resenting the 95% confidence intervals. All patients are included from the 3 hospita
es.by
n-
o-
l,
.mogramposition (Supplementary Table 4). There was no difference be-
tween the two NAC regimens. If we reflect clinical practice worldwide
and focus on those patients over the 150 line therewasnodifference be-
tween regimens (ALT N 1000: 21 h 20/485; SNAP 20/474. Absolute dif-
ference 0.1% (−2.5 to 2.7)). For those patients treated with the SNAP
regimen, the number of bags of NAC received by different nomogram
groups is presented in Supplementary Fig. 2. Themode average number
of bags was 2 for all groups but the number of patients receiving ex-
tended treatment is increased in the higher nomogram bands.
3.5. Scottish Health Record Linkage
Data linkage using national Scottish datasets was performed to de-
termine patient outcome after discharge. This approach captures admis-
sions to all Scottish hospitals and all deaths and facilitates efficient
patient follow up to determine pre-defined outcomes. In those RIE pa-
tients coded with paracetamol overdose (T39.1) as their primary dis-
charge diagnosis or with T39.1 recorded in any diagnostic position,
none were readmitted with, or died from, liver failure within 7 or
30 days of their index presentation. The incidence of transfer to the
Scottish Liver Transplantation Unit was similar in the time windows
corresponding to RIE using the 21 h and SNAP regimens (Table 3).
4. Discussion
Paracetamol overdose is one of themost commonmedical emergen-
cies in the UK and worldwide. NAC is an effective antidote but the
widely used 21 h regimen produces a high rate of ADRs and necessitates
prolonged hospital admission. We have previously shown that the
shorter ‘SNAP’ regimen is associated with improved patient safety due
to a substantial reduction in the incidence of anaphylactoid reactions.
We now show in this paper that the two regimens are of similar efficacy
in unselected patients.
The SNAP trial recruited a selected sub-groupof single acute paracet-
amol overdose patients that were able and willing to consent to this
randomised controlled trial. In the present paper we describe extension
of the SNAP regimen into routine clinical practice. The SNAP trial was
not large enough to confidently inform clinicians about whether the
SNAP 12 h regimen is as effective as the 21 h regimen at preventing
liver toxicity. In the present study, we have combined data from three
specialist UK clinical toxicology units in Edinburgh, Newcastle and
London to describe the safety and efficacy of the SNAP regimen when
used in routine clinical practice. In the population as a whole the SNAP
regimen is as effective as the 21 h NAC regimen with regard to
preventing liver injury. The width of the confidence intervals in our
point estimates of the difference between the 21 h and SNAP regi-
mens could be used as a guide as to whether national guidelines
and individual hospitals should switch to using the 12 h regimen or
whether larger studies are still required. For example, if 4% of pa-
tients develop an ALT N 1000 U/L with the 21 h NAC regimen, clini-
cians can have 95% confidence that the 12 h regimen will lead to no
ig. 2. The difference in the frequency of liver injury between the 21 h NAC regimen and
e SNAP regimen when the population is sub-divided by overdose pattern. Liver injury
presented as ALT N 1000 U/L (A) and INR N 2 (B). Acute single overdoses are sub-
ivided by the time from overdose to starting NAC treatment. The unknown group took
single overdose at an unknown time. Staggered and therapeutic excess patterns are
lso presented. Data are presented as the absolute differences (%) with the error bars
epresenting the 95% confidence intervals. Patients without baseline ALT or INR values
nd those reaching the endpoints before starting NAC were excluded. Patients from all 3
ites are included.
able 3
atient outcomes derived from data linkage of Royal Infirmary of Edinburgh admissions
ith paracetamol overdose (T39.1 code ICD10) as the primary diagnosis or anywhere in
e diagnostic coding. Patient admissions were from 28th September 2012–28th Septem-
er 2015 (21h regimen) and28th September 2015–27th September 2017 (12h regimen).
or the primary diagnosis table N numbers were 1913 and 1031 for the 21 h and 12 h reg-
ens. For the any diagnostic position table N numbers were 3017 and 1507 for the 21 h
nd 12 h regimens. Data are presented as the number and the percentage of admissions.
RIE
21 h regimen
RIE
12 h regimen
Absolute difference
(95% CI)
Primary diagnosis T39.1
Readmission in 7 days
Liver failure 0 0 0% (−0.3 to 0.2)
Paracetamol OD 29 (1.5) 17 (1.7) 0.1% (−0.7 to 1.2)
All other cases 45 (2.4) 23 (2.2) −0.1% (−1.2 to 1.1)
Readmission in 30 days
Liver failure 0 0 0% (−0.3 to 0.2)
Paracetamol OD 81 (4.2) 66 (6.4) 2.1% (0.5 to 4)
All other cases 136 (7.1) 72 (7.0) −0.1% (−1.9 to 1.9)
Death within 7 days
Liver failure 0 0 0% (−0.3 to 0.2)
All other cases 0 1 (0.2) 0.1% (0.1 to 0.5)
Death within 30 days
Liver failure 0 0 0% (−0.3 to 0.2)
All other cases 0 1 (0.2) 0.1% (0.1 to 0.5)
Liver unit transfer
7 days 4 (0.4) 1 (0.2) −0.1% (−0.5 to 0.4)
30 days 6 (0.6) 1 (0.2) −0.2 (−0.6 to 0.3)
Any position T39.1
Readmission in 7 days
Liver failure 0 0 0% (−0.1 to 0.3)
Paracetamol OD 32 (1.1) 21 (1.4) 0.3% (−0.3 to 1.1)
All other cases 63 (2.1) 36 (2.4) 0.3% (−0.5 to 1.3)
Readmission in 30 days
Liver failure 0 0 0% (−0.1 to 0.3)
Paracetamol OD 90 (3.0) 76 (5.0) 2.1% (0.9 to 3.4)
All other cases 190 (6.3) 114 (7.6) 1.3% (−0.2 to 2.9)
Death within 7 days
Liver failure 0 0 0% (−0.1 to 0.3)
All other cases 2 (0.1) 1 (0.1) 0% (−0.1 to 0.3)
Death within 30 days
Liver failure 0 0 0% (−0.1 to 0.3)
All other cases 14 (0.9) 1 (0.1) −0.4% (−0.04 to−0.7)
Liver unit transfer
7 days 10 (0.6) 2 (0.2) −0.2% (−0.5 to 0.2)
30 days 12 (0.7) 2 (0.2) −0.3 (−0.6 to 0.1)
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ALT activity.
This paper demonstrates reduced anaphylactoid reactions in unse-
lected patient populations treated with the SNAP regimen across 3 UK
hospitals. While such reactions are not usually life-threatening, they
are unpleasant and lead to treatment interruption, treatment refusal
and reluctance of physicians to treat patients with a history of previous
reactions. In the Edinburgh dataset there were a number of patients
who were treated with both the 21 h NAC and SNAP regimens. In
these repeat presenters the incidence of anaphylactoid reactions wasr-
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awhohave had reactions to the 21 hNAC regimen are less likely to have a
repeat reaction if treated with the SNAP regimen. This current paper re-
produces the principal findings from the SNAP trial in routine clinical
practice, and thus provides external validity.
The SNAP regimen is shorter than current treatment so has the po-
tential to reduce length of hospital stay for patients who do not develop
liver toxicity. Defining the criteria for discharge from hospital immedi-
ately after completing the 12 h SNAP regimen will be a focus for future
research and guideline development. In both the 21 h regimen and
SNAP the dose of NAC is based solely on body weight and not any of
the variables identified as being associated with increased risk of liver
injury in our models (presentation paracetamol concentration, ALT
and INR). Further clinical data and researchwill be needed to determine
whether there are sub-groups of patients who would be optimally
treated with lower or higher doses of NAC, such as patients presenting
following large overdoses [15,16], and/or whether other biomarkers
currently being developed could help identify patients at greater risk
[17].
4.1. Limitations
From the data in this paper we cannot confidently determine
whether there are sub-groups of overdose patients thatwould be better
treated with the 21 h or SNAP protocol. When clinically relevant sub-
groups were investigated, the SNAP protocol appeared better in
17J.M. Pettie et al. / EClinicalMedicine 11 (2019) 11–17staggered overdose and the21h protocol better in late presenting single
overdoses. However, these effects were not significant once differences
in baseline variableswere adjusted for. In patientswith high blood para-
cetamol concentrations the two regimens did not differ. Substantially
larger studies are required to identify any real sub-group differences.
This paper describes the results of an observational study before and
after a change in treatment so is inherently at risk of confounding asso-
ciated with this study type. However, it is reassuring that the patient
groups were largely similar in their demographics and there were no
changes to themanagement of paracetamol overdose other than the in-
troduction of the SNAP regimen in the study period. Furthermore, the
assessment of efficacy by use of blood results and data linked outcomes
is relatively objective. This report uses blood results from routine clini-
cal practice and there are therefore missing data. For example, there
were significantly more patients in the SNAP regimen who did not
have blood taken at 20 h. This is because the addition of blood sampling
at the end of the 12 h regimen gave patients and treating clinicians the
confidence to omit the repeat blood tests at 20h. Those patientswithout
blood results at 20 h had 10 h blood results that indicate most were at
low risk of developing subsequent liver injury, but this cannot be ex-
cluded. Data linkage demonstrated that nopatients returned to any hos-
pital in Scotland with liver failure at 7 and 30 days after discharge.
Furthermore, the overall hospital readmission rate was similar for the
21 h NAC and SNAP regimens. This suggests that the patients who did
not have blood tests at 20 h did not come to serious harm after hospital
discharge. Finally, NAC can cause small increases in INR in the absence of
liver injury and this phenomenon could account for a small proportion
of the cases of INR N 2 rise [18]. As the SNAP regimen delivers NAC at
a faster rate, in the absence of liver injury it can produce a larger in-
crease in INR compared to the 21 h regimen (a false positive result).
However, this NAC-induced increase in INR is unlikely to exceed the
INR N 3 cut-off used in this paper.
In summary, 2 years of experience of using the SNAP regimen con-
firms that it produces fewer ADRs and has similar efficacy with regard
to preventing liver injurywhen compared to the 21 hNAC regimen. Fur-
ther clinical development and adoption of the SNAP regimen could im-
prove treatment safety for this patient group, reduce the need for
treatment interruptions and potentially shorten the length of treatment
without compromising antidote effectiveness.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.eclinm.2019.04.005.
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